Work

Addition of Bortezomib (Velcade) to AML Induction Chemotherapy Is Well Tolerated and Results in a High Complete Remission Rate.

Year: 2005

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v106.11.2782.2782

Authors: Eyal C. Attar, Daniel J. De Angelo, Andres Sirulnik, Martha Wadleigh, Karen K. Ballen, Kenneth B. Miller, Ilene Galinsky, Donna Neuberg, Elizabeth Trehu, David Schenkein, Richard M. Stone, Philip C. Amrein

Institutions: Massachusetts General Hospital, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Takeda Oncology (United States)

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2571142173

FWCI: 1.249

Cites:

Cited by: 8

Related to: 10